PPARG and fatty liver disease: Other PPARγ agonists, such as pioglitazone, also attenuate hepatic steatosis, inflammation, and fibrosis to a degree similar to that of telmisartan, but also affect systemic characteristics such as lipid metabolism and body weight such that rats treated with pioglitazone exhibit increases in body weight and subcutaneous fat.